ISRCTN34651483已完成未知
Randomised study of dacarbazine versus dacarbazine plus G3139 (Bcl-2 Antisense Oligonucleotide, Genasense™) in patients with advanced malignant melanoma
Genta Incorporated (USA)0 个研究点目标入组 750 人开始时间: 2002年11月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 750
研究概览
简要总结
2006 results in https://www.ncbi.nlm.nih.gov/pubmed/16966688 (added 08/02/2019)
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Measurable disease
- •2. No brain metastases
- •3. At least 4 weeks since biological therapy, radiation therapy or surgery
- •4. No previous chemotherapy
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
1 期
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy (PROMIT)MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864MelanomaEUCTR2017-003556-23-DEniversity Hospital of the Friedrich-Alexander University Erlangen-Nürnberg38
已完成
3 期
Trial of Dacarbazine With or Without Genasense in Advanced MelanomaMelanomaNCT00518895Genta Incorporated300
已完成
3 期
A randomised trial of adjuvant procarbazine, CCNU, vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (BR11) - EORTCBrain tumourAnaplastic oligodendroglioma, brain tumoursCancerISRCTN32891249Medical Research Council (MRC) (UK)368
已完成
3 期
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With SchizophreniaSchizophreniaNCT01412060Forest Laboratories765
进行中（未招募）
不适用
DETECT-01 DETICENE EVALUATION FOR COLORECTAL CANCER THERAPYEUCTR2011-002080-21-ITAZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)